Deals channel feed

Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

4 years ago
Financing
Pharma

Eli Cas­din co-leads $250M in­fu­sion in­to mi­croflu­idics play­er that land­ed NIH fund­ing for Covid-19 test­ing

4 years ago
Financing
Outsourcing

So what ex­act­ly does Ver­i­ly do? A new deal with L'Oréal does­n't clear up much

4 years ago

Faced with in­tense in­vestor back­lash, Unilever now says $68B is its fi­nal of­fer for GSK con­sumer health­care busi­ness

4 years ago

UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

4 years ago

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron as CEO in a stun­ner? Let Rick Klaus­ner ex­plain

4 years ago
Cell/Gene Tx

British bil­lion­aire Mike Platt hops on board a Lon­don start­up look­ing at drug dis­cov­ery from a dif­fer­ent an­gle

4 years ago
Financing
Startups

Se­ma4 shells out $623M to scoop up a lead­ing di­ag­nos­tics play­er and its trove of da­ta

4 years ago

Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

4 years ago

An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

4 years ago
Startups

Ready for an M&A fight? Af­ter GSK shunned $68B of­fer, Unilever says it's still in hunt for con­sumer health JV

4 years ago
Pharma

Vir ex­pands part­ner­ship with Gates Foun­da­tion, adding $50M for HIV and malar­ia an­ti­body re­search ini­tia­tive

4 years ago

Bio­phar­ma deal­mak­ers re­flect on last year's shifts in the mar­ket, as they gear up for an­oth­er 'ac­tive' year ahead

4 years ago

Af­ter nab­bing two AI-gen­er­at­ed mol­e­cules, As­traZeneca re­turns to Benev­o­len­tAI with new col­lab­o­ra­tion

4 years ago
AI

#JPM22 - Deal­mak­ing in 2022: What's Big Phar­ma look­ing for and what is it will­ing to pay?

4 years ago

Three years, a clin­i­cal hold and a death lat­er, Sarep­ta aban­dons part­nered piv­otal-stage gene ther­a­py

4 years ago
Cell/Gene Tx

Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

4 years ago

Pfiz­er's hot start to the new year con­tin­ues with li­cens­ing deal for mys­te­ri­ous biotech's sol­id tu­mor bis­pecifics

4 years ago

Busy Am­gen swings an­oth­er deal, this time with RNA drug­ging play­er Ar­rakis for 'sev­er­al bil­lion'

4 years ago

A new AI start­up has emerged, and Pfiz­er likes what it sees

4 years ago
Financing
Startups

Bris­tol My­ers takes a swing at 'off-the-shelf' cell ther­a­pies in $150M cash li­cens­ing pact with Cen­tu­ry

4 years ago
Cell/Gene Tx

Bris­tol My­ers to spend $50B on deals, buy­backs in next 3 years — al­though BD chief notes find­ing the right deal still 'very hard'

4 years ago

Con­tin­u­ing push be­yond Covid-19 vac­cines, Mod­er­na part­ners with 'CAR-M' biotech on in vi­vo can­cer cell ther­a­pies

4 years ago
Cell/Gene Tx

Take­da kicks off JPM week with M&A — buy­ing out an­oth­er gam­ma/delta spin­out and div­ing in­to a new ‘swim lane’

4 years ago
R&D
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times